The Role of Immunotherapy in ALL and its Impact on Healthcare

Background ALL is a rare but aggressive malignant cancer caused by uncontrolled proliferation of lymphoblasts which disrupt normal organ function.  Review of Interventions In this article we will discuss how genomic medicine allows better risk stratification and early identification of certain genetic alterations. Different immunotherapies will be reviewed, their mechanism of action and novel upcoming therapies.  Assessment of Impact The addition of immunotherapy has improved clinical outcomes for patients, increasing overall survival and having a lower AE profile.  Conclusion Immunotherapy offers a more targeted approach in ALL management, despite high initial costs, it can prove to be cost-effective and inevitably reduce burden on a health system.